Dear Mrs Gauer,

I hope this email finds you well.

As you may have seen, we have just announced an agreement with BARDA to accelerate the global clinical development program for the COVID-19 vaccine candidate. As you know, we intend to offer the vaccine at no profit to support global access during the pandemic.

Given the complexity of the challenge, we cannot do this alone and are partnering with international organisations and governments to make our vaccine globally available. We have been extremely grateful for the engagements with the EU to date to ensure that the vaccine is developed, manufactured, and distributed equitably, as soon as possible, including of course for the European population.

Many thanks for all your support and collaboration. We are currently in the process of completing the questionnaire following our meeting and hope to be able to get back to you shortly on this.

Best regards,

AstraZeneca

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number 03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail,
highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com.